- Market Capitalization, $K 12,389
- Shares Outstanding, K 5,340
- Annual Sales, $ 0 K
- Annual Income, $ -49,910 K
- 60-Month Beta -0.04
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+0.73 (+45.91%)since 12/30/22
| || |
-0.44 (-15.94%)since 10/28/22
| || |
-3.44 (-59.70%)since 01/28/22
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to...
Minerva Neurosciences: Q3 Earnings Snapshot
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.
A handful of analysts offering 12-month price forecasts for Minerva Neuroscienes Inc (NASDAQ: NERV) have elected a median price target of $17.
Biopharmaceutical company Minerva Neurosciences (NERV) delivered considerable losses in its last quarter. Investors are increasingly concerned about the company’s massive debt burden and increased cash...
Morning Markets September S&P 500 futures (ESU22 ) this morning are down -0.73% at a 1-month low. Stock indexes this morning are extending last Friday’s rout after Fed Chair Powell signaled the Fed...
Minerva Neurosciences (NERV) and Vertex Pharmaceuticals (VRTX) are expected to benefit from the rising number of chronic diseases and continued technological advancements in the industry. Since NERV has...
Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.